journal
MENU ▼
Read by QxMD icon Read
search

Journal of Thoracic Oncology

journal
https://www.readbyqxmd.com/read/28342816/anti-neutrophil-cytoplasmic-antibody-associated-rapid-progressive-glomerulonephritis-rpgn-after-pembrolizumab-treatment-in-thymic-epithelial-tumor-a-case-report
#1
Mi Hwa Heo, Hee Kyung Kim, Hansang Lee, Myung-Ju Ahn
No abstract text is available yet for this article.
March 22, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28342690/correlation-causation-and-confounding-what-is-the-true-risk-of-lung-cancer-following-breast-cancer-radiotherapy
#2
EDITORIAL
Suresh Senan, Alexander V Louie
No abstract text is available yet for this article.
March 22, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28315738/pulmonary-sarcomatoid-carcinomas-commonly-harbor-either-potentially-targetable-genomic-alterations-or-high-tumor-mutational-burden-as-observed-by-comprehensive-genomic-profiling
#3
Alexa B Schrock, Shuyu D Li, Garrett M Frampton, James Suh, Eduardo Braun, Ranee Mehra, Steven Buck, Jose A Bufill, Nir Peled, Nagla Abdel Karim, Cynthia Hsieh, Manuel Doria, James Knost, Rong Chen, Sai-Hong Ignatius Ou, Jeffrey S Ross, Philip J Stephens, Paul Fishkin, Vincent A Miller, Siraj M Ali, Balazs Halmos, Jane J Liu
BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC) is a high-grade non-small cell lung carcinoma (NSCLC) characterized by poor prognosis and resistance to chemotherapy. Development of targeted therapeutic strategies for PSC has been hampered due to limited and inconsistent molecular characterization. METHODS: Hybrid-capture based comprehensive genomic profiling (CGP) was performed on DNA from 15,867 FFPE NSCLCs including 125 PSCs (0.8%). Tumor mutational burden (TMB) was calculated from 1...
March 15, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28302568/mutational-profile-from-targeted-ngs-predicts-survival-in-ldct-screening-detected-lung-cancers
#4
Carla Verri, Cristina Borzi, Todd Holscher, Matteo Dugo, Andrea Devecchi, Katherine Drake, Stefano Sestini, Paola Suatoni, Elisa Romeo, Gabriella Sozzi, Ugo Pastorino, Mattia Boeri
BACKGROUND: The issue of overdiagnosis in low-dose computed tomography (LDCT)-screening trials could be addressed by the development of complementary biomarkers able to improve detection of aggressive disease. The mutation profile of LDCT screening-detected lung tumours is currently unknown. METHODS: Targeted next-generation sequencing was performed in 94 LDCT screening-detected lung tumours. Associations with clinicopathologic features, survival and the risk profile of a plasma microRNA signature classifier (MSC) were analyzed...
March 13, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28291724/successful-osimertinib-rechallenge-after-severe-osimertinib-induced-hepatotoxicity
#5
LETTER
Hironori Yoshida, Young Hak Kim
No abstract text is available yet for this article.
March 10, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28286243/use-of-stereotactic-ablative-radiotherapy-sabr-in-non-small-cell-lung-cancer-measuring-more-than-5-cm
#6
Hilâl Tekatli, Saar van 't Hof, Esther J Nossent, Max Dahele, Wilko F A R Verbakel, Ben J Slotman, Suresh Senan
BACKGROUND: Stereotactic ablative radiotherapy (SABR) is currently not the guideline recommended treatment for lung tumors measuring more than 5 cm. However, improvements in radiotherapy techniques have led to an increasing use of SABR for larger tumors. METHODS: We analyzed the clinical outcomes in patients with a primary or recurrent non-small cell lung cancer measuring >5 cm, treated with 5 or 8 fractions of SABR at our center. Patients who had prior thoracic radiotherapy were excluded...
March 7, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28286242/sub-clonal-therapy-by-two-egfr-tkis-guided-by-sequential-plasma-cell-free-dna-in-egfr-mutated-lung-cancer
#7
Nir Peled, Laila C Roisman, Benjamin Miron, Raphael Pfeffer, Richard B Lanman, Maya Ilouse, Addie Dvir, Lior Soussan-Gutman, Fabrice Barlesi, Gabi Tarcic, Oded Edelheit, David Gandara, Yehiel Elkabetz
No abstract text is available yet for this article.
March 7, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28274743/tolerable-and-effective-combination-of-full-dose-crizotinib-and-osimertinib-targeting-met-amplification-sequentially-emerging-after-t790m-positivity-in-egfr-mutant-non-small-cell-lung-cancer
#8
Emily R York, Marileila Varella-Garcia, Tami J Bang, Dara L Aisner, D Ross Camidge
No abstract text is available yet for this article.
March 6, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28259750/long-term-outcomes-of-salvage-stereotactic-ablative%C3%A2-radiotherapy-for-isolated-lung-recurrence-of-non-small-cell-lung-cancer-a-phase-ii-clinical-trial
#9
Bing Sun, Eric D Brooks, Ritsuko Komaki, Zhongxing Liao, Melenda Jeter, Mary McAleer, Peter A Balter, James D Welsh, Michael O'Reilly, Daniel Gomez, Stephen M Hahn, Boris Sepesi, David C Rice, John V Heymach, Joe Y Chang
OBJECTIVES: Our goal was to evaluate stereotactic ablative radiotherapy (SABR) as a salvage option for isolated recurrence of NSCLC in the lung parenchyma after definitive treatment of stage I to III disease. METHODS: Patients who had histologically confirmed, positron emission tomography-staged, isolated NSCLC recurring locally or metastasis in the lung parenchyma (≤3 cm, suitable for SABR) after previous definitive treatment were prospectively enrolled in this trial and treated with volumetric, image-guided SABR to 50 Gy in four fractions...
March 1, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28257959/the-immune-microenvironment-genome-wide-copy-number-aberrations-and-survival-in-mesothelioma
#10
Bibhusal Thapa, Adriana Salcedo, Xihui Lin, Marzena Walkiewicz, Carmel Murone, Malaka Ameratunga, Khashyar Asadi, Siddhartha Deb, Stephen Arthur Barnett, Simon Knight, Paul Mitchell, D Neil Watkins, Paul C Boutros, Thomas John
INTRODUCTION: Results of recent clinical studies of immune checkpoint inhibitors in malignant pleural mesothelioma (MPM) have dampened initial enthusiasm. However, the immune environment and targets of these treatments such as program cell death protein 1 (PD-1) and its ligand PD-L1 have not been well characterised in MPM. Using a large cohort of patients, we investigated PD-L1 expression, immune infiltrates and genome-wide copy number status and correlated them to clinicopathological features...
February 28, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28257958/prognostic-impact-of-the-findings-on-thin-section-computed-tomography-in-patients-with-subcentimeter-non-small-cell-lung-cancer
#11
Aritoshi Hattori, Takeshi Matsunaga, Takuo Hayashi, Kazuya Takamochi, Shiaki Oh, Kenji Suzuki
INTRODUCTION: Subcentimeter non-small cell lung cancer (NSCLC) is not always an early-stage disease despite its small tumor size. We investigated the prognostic impact of such cancers based on the findings of thin-section computed tomography (CT). METHODS: We evaluated the clinicopathological features and prognosis of 328 surgically resected clinical-N0 NSCLC 1.0cm or less in size. Consolidation tumor ratio (CTR) was evaluated for all, and tumors were classified into 3 group, namely, pure-ground glass opacity (GGO) (CTR=0, n=139), part-solid (0<CTR<1...
February 28, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28238961/alectinib-for-patients-with-alk-rearrangement-positive-non-small-cell-lung-cancer-and-a-poor-performance-status-lung-oncology-group-in-kyushu-1401
#12
Eiji Iwama, Yasushi Goto, Haruyasu Murakami, Taishi Harada, Shinsuke Tsumura, Hiroyuki Sakashita, Yoshiaki Mori, Noriaki Nakagaki, Yuka Fujita, Masahiro Seike, Akihiro Bessho, Manabu Ono, Akihito Okazaki, Hiroaki Akamatsu, Ryotaro Morinaga, Shinichiro Ushijima, Takayuki Shimose, Shoji Tokunaga, Akinobu Hamada, Nobuyuki Yamamoto, Yoichi Nakanishi, Kenji Sugio, Isamu Okamoto
INTRODUCTION: Alectinib has shown marked efficacy and safety in patients with ALK rearrangement-positive non-small cell lung cancer (NSCLC) and a good performance status (PS). It has remained unclear whether alectinib might also be beneficial for such patients with a poor PS. METHODS: Eligible patients with advanced ALK rearrangement-positive NSCLC and a PS of 2 to 4 received alectinib orally at 300 mg twice daily. The primary end point of the study was objective response rate (ORR), and the most informative secondary end point was rate of PS improvement...
February 23, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28193529/heterogeneity-in-immune-marker-expression-after-acquisition-of-resistance-to-egfr-kinase-inhibitors-analysis-of-a-case-with-small-cell-lung-cancer-transformation
#13
Kenichi Suda, Isao Murakami, Hui Yu, Jihye Kim, Kim Ellison, Christopher J Rivard, Tetsuya Mitsudomi, Fred R Hirsch
INTRODUCTION: Expression of immune-markers is of scientific interest due to their potential roles as predictive biomarkers for immunotherapy. Although the microenvironment of metastatic tumors and/or therapy-inducible histological transformation may affect the expression of these immune-markers, there is little data regarding this context. METHODS: A 76-year-old never-smoking female with epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma (AC) acquired resistance to gefitinib...
February 10, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28189832/characteristics-and-outcomes-of-patients-with-lung-cancer-harboring-multiple-molecular-alterations-results-from-the-ifct-study-biomarkers-france
#14
Nicolas Guibert, Fabrice Barlesi, Renaud Descourt, Hervé Léna, Benjamin Besse, Michèle Beau-Faller, Jean Mosser, Eric Pichon, Jean-Philippe Merlio, L'Houcine Ouafik, François Guichard, Bénédicte Mastroianni, Lionel Moreau, Annie Wdowik, Jean-Christophe Sabourin, Antoinette Lemoine, Pascale Missy, Alexandra Langlais, Denis Moro-Sibilot, Julien Mazieres
INTRODUCTION: Little is known about the prevalence, prognosis and response to treatment of advanced non-small cell lung cancer (NSCLC) harboring multiple genomic alterations. METHODS: The French Biomarkers France database (IFCT) including 17,664 patients was used. The prevalence of multiple alterations, their associations, impact on prognosis (overall survival: OS) and their response to targeted or conventional treatments (progression free survival: PFS; objective response rate: ORR), were assessed and compared with those of patients harboring single or no mutation...
February 9, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28179162/loss-of-p16-ink4a-expression-and-homozygous-cdkn2a-deletion-are-associated-with-worse-outcome-and-younger-age-in-thymic-carcinomas
#15
Scott W Aesif, Marie Christine Aubry, Eunhee S Yi, Sara M Kloft-Nelson, Sarah M Jenkins, Grant M Spears, Patricia T Greipp, William R Sukov, Anja C Roden
INTRODUCTION: Thymic carcinomas are aggressive tumors. Biomarkers and alternative treatment modalities are needed. We studied the expression of p16 and cytogenetic abnormalities of cyclin-dependent kinase inhibitor 2A gene (CDKN2A) and correlated findings with clinical features and outcome in a large cohort of thymic carcinomas. METHODS: Thymic carcinomas (1963-2013) were stained with p16. Fluorescence in situ hybridization was utilized to assess for the presence of CDKN2A gene (at 9p21)...
February 5, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28167203/erbb2-mutated-metastatic-non-small-cell-lung-cancer-response-and-resistance-to-targeted-therapies
#16
Jody C Chuang, Henning Stehr, Ying Liang, Millie Das, Jane Huang, Maximilian Diehn, Heather A Wakelee, Joel W Neal
INTRODUCTION: Erb-b2 receptor tyrosine kinase 2 gene (ERBB2) (also called HER2) has long been recognized as an oncogenic driver in some breast and gastroesophageal cancers in which amplification of this gene confers sensitivity to treatment with Erb-b2 receptor tyrosine kinase 2 (ERBB2)-directed agents. More recently, somatic mutations in ERBB2 have been reported in 1% to 2% of patients with lung adenocarcinoma. Previous case series have suggested clinical tumor responses using anti-ERBB2 small molecules and antibody therapies...
February 4, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28161554/maintenance-sunitinib-following-initial-platinum-based-combination-chemotherapy-in-advanced-stage-iiib-iv-non-small-cell-lung-cancer-a%C3%A2-randomized-double-blind-placebo-controlled-phase-iii-study-calgb-30607-alliance
#17
Maria Q Baggstrom, Mark A Socinski, Xiaofei F Wang, Lin Gu, Thomas E Stinchcombe, Martin J Edelman, Sherman Baker, Josephine Feliciano, Paul Novotny, Olwen Hahn, Jeffrey A Crawford, Everett E Vokes
INTRODUCTION: The aim of this study was to evaluate efficacy of maintenance sunitinib after first-line chemotherapy for stage IIIB/IV NSCLC. METHODS: Cancer and Leukemia Group B 30607 trial was a randomized, double-blind, placebo-controlled, phase III study that enrolled patients without progression after four cycles of first-line platinum-based doublet chemotherapy with or without bevacizumab. Bevacizumab was allowed only during the four cycles of chemotherapy...
February 1, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28214559/radiation-therapy-for-invasive-breast-cancer-increases-the-risk-of-second-primary-lung-cancer-a-nationwide-population-based-cohort-analysis
#18
Yi-Jhih Huang, Tsai-Wang Huang, Fu-Huang Lin, Chi-Hsiang Chung, Chang-Huei Tsao, Wu-Chien Chien
INTRODUCTION: Although the risk factors for lung cancer are well documented, it remains unclear if previous radiation therapy (RT) to treat breast cancer (BC) increases the incidence of second primary lung cancer. We determined the overall incidence of second primary lung cancer after previous RT for all clinical stages of BC. METHODS: After analyzing the Longitudinal Health Insurance Database, 986,713 individuals were randomly enrolled from 2000 to 2010 for cohort analysis...
January 31, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28147239/a-sensitive-alk-immunohistochemistry-companion-diagnostic-test-identifies-patients-eligible-for-treatment-with-crizotinib
#19
Trish Thorne-Nuzzo, Crystal Williams, Alice Catallini, June Clements, Shalini Singh, James Amberson, Kim Dickinson, Zoran Gatalica, Steffan N Ho, Isabell Loftin, Abigail McElhinny, Penny Towne
INTRODUCTION: The availability of high-quality, rigorously validated diagnostic tests that can be broadly implemented is necessary to efficiently identify patients with anaplastic lymphoma kinase (ALK)-positive NSCLC who can potentially benefit from treatment with crizotinib. Here we present data on the recently approved Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems, Tucson, AZ), the only immunohistochemistry (IHC)-based assay linked to treatment outcome. METHODS: NSCLC specimens prospectively tested for anaplastic lymphoma receptor tyrosine kinase gene (ALK) status by flourescent in situ hybridization (FISH) in the PROFILE 1014 clinical trial of crizotinib versus chemotherapy (N = 1018, including 179 ALK-positive and 754 ALK-negative specimens) were evaluated using the ALK (D5F3) CDx assay...
January 29, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28132868/lag-3-protein-expression-in-non-small-cell-lung-cancer-and-its-relationship-with-pd-1-pd-l1-and-tumor-infiltrating-lymphocytes
#20
Yayi He, Hui Yu, Leslie Rozeboom, Christopher J Rivard, Kim Ellison, Rafal Dziadziuszko, Kenichi Suda, Shengxiang Ren, Chunyan Wu, Likun Hou, Caicun Zhou, Fred R Hirsch
INTRODUCTION: Immunotherapy targeting the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) checkpoint has shown promising efficacy in patients with NSCLC. Lymphocyte activating 3 gene (LAG-3) is another important checkpoint, and its role in NSCLC is still not clear. In this study we investigated lymphocyte activing 3 (LAG-3) protein expression; its correlation with PD-1, PD-L1, and tumor-infiltrating lymphocytes (TILs); and its association with survival in NSCLC. METHODS: The expression of LAG-3 (EPR4392 [Abcam, Cambridge, MA]) protein was assessed in 55 NSCLC cell lines by immunohistochemistry...
January 26, 2017: Journal of Thoracic Oncology
journal
journal
41363
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"